US 11,958,877 B2
Nucleotide analogues
Ronald Graham, Carlsbad, CA (US); Olga Adelfinskaya, San Marcos, CA (US); Megha Cila, San Diego, CA (US); Rodrigo Rodriguez, San Diego, CA (US); Abrehet Abdu, San Diego, CA (US); and Eli N. Glezer, Del Mar, CA (US)
Assigned to Singular Genomics Systems, Inc., San Diego, CA (US)
Filed by Singular Genomics Systems, Inc., San Diego, CA (US)
Filed on Mar. 6, 2023, as Appl. No. 18/178,802.
Application 18/178,802 is a continuation of application No. 17/287,255, previously published as PCT/US2019/057842, filed on Oct. 24, 2019.
Claims priority of provisional application 62/841,146, filed on Apr. 30, 2019.
Claims priority of provisional application 62/789,877, filed on Jan. 8, 2019.
Claims priority of provisional application 62/750,552, filed on Oct. 25, 2018.
Prior Publication US 2023/0203083 A1, Jun. 29, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07H 19/14 (2006.01); C07H 19/10 (2006.01); C07H 19/20 (2006.01); C12Q 1/6869 (2018.01); C12Q 1/6876 (2018.01)
CPC C07H 19/14 (2013.01) [C07H 19/10 (2013.01); C07H 19/20 (2013.01); C12Q 1/6869 (2013.01); C12Q 1/6876 (2013.01)] 21 Claims
 
1. A kit comprising a labeled nucleotide, wherein the labeled nucleotide comprises:
(i) a cleavable moiety covalently bound to the 3′ oxygen of said labeled nucleotide, wherein the cleavable moiety has the formula -L1P-S—S—R6P(I); and
(ii) a nucleobase linked via a covalent linker to a first detectable moiety, wherein said covalent linker comprises

OG Complex Work Unit Chemistry
 wherein,
R102 is unsubstituted C1-C4 alkyl;
L1P is a substituted methylene, wherein L1P is substituted with a substituted or unsubstituted alkyl, or a substituted or unsubstituted heteroalkyl; and
R6P is unsubstituted methyl or unsubstituted ethyl.